Clinically tractable outcome prediction of non-WNT/non-SHH medulloblastoma based on TPD52 IHC in a multicohort study

International consensus and the 2021 WHO classification recognize eight molecular subgroups among non-WNT/non-SHH (Group 3/4) medulloblastoma, representing approximately 60% of tumors. However, very few clinical centers worldwide possess the technical capabilities to determine DNA methylation profil...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Delaidelli, Alberto (VerfasserIn) , Dunham, Christopher (VerfasserIn) , Santi, Mariarita (VerfasserIn) , Negri, Gian Luca (VerfasserIn) , Triscott, Joanna (VerfasserIn) , Zheludkova, Olga (VerfasserIn) , Golanov, Andrey (VerfasserIn) , Ryzhova, Marina (VerfasserIn) , Okonechnikov, Konstantin (VerfasserIn) , Schrimpf, Daniel (VerfasserIn) , Stichel, Damian (VerfasserIn) , Ellison, David W. (VerfasserIn) , Deimling, Andreas von (VerfasserIn) , Kool, Marcel (VerfasserIn) , Pfister, Stefan (VerfasserIn) , Ramaswamy, Vijay (VerfasserIn) , Korshunov, Andrey (VerfasserIn) , Taylor, Michael D. (VerfasserIn) , Sorensen, Poul H. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 05 2022
In: Clinical cancer research
Year: 2022, Jahrgang: 28, Heft: 1, Pages: 116-128
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-21-2057
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-21-2057
Volltext
Verfasserangaben:Alberto Delaidelli, Christopher Dunham, Mariarita Santi, Gian Luca Negri, Joanna Triscott, Olga Zheludkova, Andrey Golanov, Marina Ryzhova, Konstantin Okonechnikov, Daniel Schrimpf, Damian Stichel, David W. Ellison, Andreas von Deimling, Marcel Kool, Stefan M. Pfister, Vijay Ramaswamy, Andrey Korshunov, Michael D. Taylor, and Poul H. Sorensen

MARC

LEADER 00000caa a2200000 c 4500
001 1815683325
003 DE-627
005 20230118151144.0
007 cr uuu---uuuuu
008 220902s2022 xx |||||o 00| ||eng c
024 7 |a 10.1158/1078-0432.CCR-21-2057  |2 doi 
035 |a (DE-627)1815683325 
035 |a (DE-599)KXP1815683325 
035 |a (OCoLC)1361697057 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Delaidelli, Alberto  |e VerfasserIn  |0 (DE-588)126700097X  |0 (DE-627)1815683058  |4 aut 
245 1 0 |a Clinically tractable outcome prediction of non-WNT/non-SHH medulloblastoma based on TPD52 IHC in a multicohort study  |c Alberto Delaidelli, Christopher Dunham, Mariarita Santi, Gian Luca Negri, Joanna Triscott, Olga Zheludkova, Andrey Golanov, Marina Ryzhova, Konstantin Okonechnikov, Daniel Schrimpf, Damian Stichel, David W. Ellison, Andreas von Deimling, Marcel Kool, Stefan M. Pfister, Vijay Ramaswamy, Andrey Korshunov, Michael D. Taylor, and Poul H. Sorensen 
264 1 |c  January 05 2022 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 02.09.2022 
520 |a International consensus and the 2021 WHO classification recognize eight molecular subgroups among non-WNT/non-SHH (Group 3/4) medulloblastoma, representing approximately 60% of tumors. However, very few clinical centers worldwide possess the technical capabilities to determine DNA methylation profiles or other molecular parameters of high risk for group 3/4 tumors. As a result, biomarker-driven risk stratification and therapy assignment constitutes a major challenge in medulloblastoma research. Here, we identify an IHC marker as a clinically tractable method for improved medulloblastoma risk stratification.We bioinformatically analyzed published medulloblastoma transcriptomes and proteomes identifying as a potential biomarker TPD52, whose IHC prognostic value was validated across three group 3/4 medulloblastoma clinical cohorts (n = 387) treated with conventional therapies.TPD52 IHC positivity represented a significant independent predictor of early relapse and death for group 3/4 medulloblastoma [HRs between 3.67 and 26.7; 95% confidence interval (CI) between 1.00 and 706.23; P = 0.05, 0.017, and 0.0058]. Cross-validated survival models incorporating TPD52 IHC with clinical features outperformed existing state-of-the-art risk stratification schemes, and reclassified approximately 50% of patients into more appropriate risk categories. Finally, TPD52 immunopositivity was a predictive indicator of poor response to chemotherapy [HR, 12.66; 95% CI, 3.53-45.40; P < 0.0001], suggesting important implication for therapeutic choices.This study redefines the approach to risk stratification in group 3/4 medulloblastoma in global practice. Because integration of TPD52 IHC in classification algorithms significantly improved outcome prediction, this test could be rapidly adopted for risk stratification on a global scale, independently of advanced but technically challenging molecular profiling techniques. 
700 1 |a Dunham, Christopher  |e VerfasserIn  |4 aut 
700 1 |a Santi, Mariarita  |e VerfasserIn  |4 aut 
700 1 |a Negri, Gian Luca  |e VerfasserIn  |4 aut 
700 1 |a Triscott, Joanna  |e VerfasserIn  |4 aut 
700 1 |a Zheludkova, Olga  |e VerfasserIn  |4 aut 
700 1 |a Golanov, Andrey  |e VerfasserIn  |4 aut 
700 1 |a Ryzhova, Marina  |e VerfasserIn  |4 aut 
700 1 |a Okonechnikov, Konstantin  |d 1987-  |e VerfasserIn  |0 (DE-588)1084245493  |0 (DE-627)848486331  |0 (DE-576)456269150  |4 aut 
700 1 |a Schrimpf, Daniel  |d 1984-  |e VerfasserIn  |0 (DE-588)1063355044  |0 (DE-627)812332032  |0 (DE-576)422629529  |4 aut 
700 1 |a Stichel, Damian  |e VerfasserIn  |0 (DE-588)1078124507  |0 (DE-627)838010059  |0 (DE-576)359423566  |4 aut 
700 1 |a Ellison, David W.  |e VerfasserIn  |4 aut 
700 1 |a Deimling, Andreas von  |d 1959-  |e VerfasserIn  |0 (DE-588)103034115X  |0 (DE-627)735093946  |0 (DE-576)378138065  |4 aut 
700 1 |a Kool, Marcel  |e VerfasserIn  |0 (DE-588)1058669753  |0 (DE-627)797393560  |0 (DE-576)414823842  |4 aut 
700 1 |a Pfister, Stefan  |d 1974-  |e VerfasserIn  |0 (DE-588)123850215  |0 (DE-627)706450930  |0 (DE-576)293908400  |4 aut 
700 1 |a Ramaswamy, Vijay  |e VerfasserIn  |4 aut 
700 1 |a Korshunov, Andrey  |e VerfasserIn  |0 (DE-588)1043235361  |0 (DE-627)770439365  |0 (DE-576)394592093  |4 aut 
700 1 |a Taylor, Michael D.  |e VerfasserIn  |4 aut 
700 1 |a Sorensen, Poul H.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Clinical cancer research  |d Philadelphia, Pa. [u.a.] : AACR, 1995  |g 28(2022), 1, Seite 116-128  |h Online-Ressource  |w (DE-627)325489971  |w (DE-600)2036787-9  |w (DE-576)094502234  |x 1557-3265  |7 nnas  |a Clinically tractable outcome prediction of non-WNT/non-SHH medulloblastoma based on TPD52 IHC in a multicohort study 
773 1 8 |g volume:28  |g year:2022  |g number:1  |g pages:116-128  |g extent:13  |a Clinically tractable outcome prediction of non-WNT/non-SHH medulloblastoma based on TPD52 IHC in a multicohort study 
856 4 0 |u https://doi.org/10.1158/1078-0432.CCR-21-2057  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220902 
993 |a Article 
994 |a 2022 
998 |g 1043235361  |a Korshunov, Andrey  |m 1043235361:Korshunov, Andrey  |p 17 
998 |g 123850215  |a Pfister, Stefan  |m 123850215:Pfister, Stefan  |d 910000  |d 910500  |d 50000  |e 910000PP123850215  |e 910500PP123850215  |e 50000PP123850215  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 15 
998 |g 1058669753  |a Kool, Marcel  |m 1058669753:Kool, Marcel  |d 50000  |e 50000PK1058669753  |k 0/50000/  |p 14 
998 |g 103034115X  |a Deimling, Andreas von  |m 103034115X:Deimling, Andreas von  |d 910000  |d 912000  |e 910000PD103034115X  |e 912000PD103034115X  |k 0/910000/  |k 1/910000/912000/  |p 13 
998 |g 1078124507  |a Stichel, Damian  |m 1078124507:Stichel, Damian  |d 140000  |d 700000  |d 716000  |e 140000PS1078124507  |e 700000PS1078124507  |e 716000PS1078124507  |k 0/140000/  |k 0/700000/  |k 1/700000/716000/  |p 11 
998 |g 1063355044  |a Schrimpf, Daniel  |m 1063355044:Schrimpf, Daniel  |d 910000  |d 912000  |e 910000PS1063355044  |e 912000PS1063355044  |k 0/910000/  |k 1/910000/912000/  |p 10 
998 |g 1084245493  |a Okonechnikov, Konstantin  |m 1084245493:Okonechnikov, Konstantin  |p 9 
999 |a KXP-PPN1815683325  |e 4184274188 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"part":{"volume":"28","text":"28(2022), 1, Seite 116-128","extent":"13","issue":"1","year":"2022","pages":"116-128"},"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"325489971","name":{"displayForm":["American Association for Cancer Research"]},"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"pubHistory":["1.1995 -"],"note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"id":{"eki":["325489971"],"zdb":["2036787-9"],"issn":["1557-3265"]},"origin":[{"publisher":"AACR","dateIssuedDisp":"1995-","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedKey":"1995"}],"corporate":[{"role":"isb","display":"American Association for Cancer Research"}],"disp":"Clinically tractable outcome prediction of non-WNT/non-SHH medulloblastoma based on TPD52 IHC in a multicohort studyClinical cancer research"}],"title":[{"title_sort":"Clinically tractable outcome prediction of non-WNT/non-SHH medulloblastoma based on TPD52 IHC in a multicohort study","title":"Clinically tractable outcome prediction of non-WNT/non-SHH medulloblastoma based on TPD52 IHC in a multicohort study"}],"physDesc":[{"extent":"13 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"doi":["10.1158/1078-0432.CCR-21-2057"],"eki":["1815683325"]},"recId":"1815683325","origin":[{"dateIssuedKey":"2022","dateIssuedDisp":" January 05 2022"}],"name":{"displayForm":["Alberto Delaidelli, Christopher Dunham, Mariarita Santi, Gian Luca Negri, Joanna Triscott, Olga Zheludkova, Andrey Golanov, Marina Ryzhova, Konstantin Okonechnikov, Daniel Schrimpf, Damian Stichel, David W. Ellison, Andreas von Deimling, Marcel Kool, Stefan M. Pfister, Vijay Ramaswamy, Andrey Korshunov, Michael D. Taylor, and Poul H. Sorensen"]},"language":["eng"],"note":["Gesehen am 02.09.2022"],"person":[{"given":"Alberto","family":"Delaidelli","role":"aut","display":"Delaidelli, Alberto"},{"display":"Dunham, Christopher","family":"Dunham","role":"aut","given":"Christopher"},{"display":"Santi, Mariarita","family":"Santi","role":"aut","given":"Mariarita"},{"given":"Gian Luca","family":"Negri","role":"aut","display":"Negri, Gian Luca"},{"given":"Joanna","display":"Triscott, Joanna","role":"aut","family":"Triscott"},{"given":"Olga","role":"aut","family":"Zheludkova","display":"Zheludkova, Olga"},{"role":"aut","family":"Golanov","display":"Golanov, Andrey","given":"Andrey"},{"given":"Marina","display":"Ryzhova, Marina","family":"Ryzhova","role":"aut"},{"given":"Konstantin","display":"Okonechnikov, Konstantin","role":"aut","family":"Okonechnikov"},{"role":"aut","family":"Schrimpf","display":"Schrimpf, Daniel","given":"Daniel"},{"given":"Damian","display":"Stichel, Damian","family":"Stichel","role":"aut"},{"role":"aut","family":"Ellison","display":"Ellison, David W.","given":"David W."},{"family":"Deimling","role":"aut","display":"Deimling, Andreas von","given":"Andreas von"},{"display":"Kool, Marcel","role":"aut","family":"Kool","given":"Marcel"},{"display":"Pfister, Stefan","family":"Pfister","role":"aut","given":"Stefan"},{"given":"Vijay","display":"Ramaswamy, Vijay","role":"aut","family":"Ramaswamy"},{"family":"Korshunov","role":"aut","display":"Korshunov, Andrey","given":"Andrey"},{"family":"Taylor","role":"aut","display":"Taylor, Michael D.","given":"Michael D."},{"given":"Poul H.","display":"Sorensen, Poul H.","family":"Sorensen","role":"aut"}]} 
SRT |a DELAIDELLICLINICALLY0520